483
Acrotech Biopharma Inc.Acrotech Biopharma Inc. – FDA 483, Jan 19, 2023
Record Details
ACROTECH BIOPHARMA, Inc. in East Windsor, NJ, was inspected regarding its post-marketing surveillance activities. The inspection revealed significant deficiencies in adverse drug experience reporting, including failures to submit serious and unexpected adverse drug experiences within 15 days, adequately investigate reported cases, and provide supporting scientific literature for alert reports. These issues indicate a systemic problem with the firm's pharmacovigilance processes.
View Company Profile
ID · c4443168-9cc6-4195-b415-a2f6e0a9ce09
Other documents for Acrotech Biopharma Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.